
Philippines: Temporary Suspension of Pre-Assessment Fees for Select FDA Applications Amid Implementation of AO No. 2024-0016
On January 24, 2025, the Food and Drug Administration (FDA) of the Philippines announced the temporary suspension of pre-assessment fees for specific applications, as outlined in FDA Advisory No. 2025-0076. This decision aims to address challenges in implementing Administrative Order (AO) No. 2024-0016, which establishes a new schedule of fees




